Once-Daily High-Dose Pindolol for Paroxetine-Refractory Premature Ejaculation: A Double-Blind, Placebo-Controlled and Randomized Study

@article{Safarinejad2008OnceDailyHP,
  title={Once-Daily High-Dose Pindolol for Paroxetine-Refractory Premature Ejaculation: A Double-Blind, Placebo-Controlled and Randomized Study},
  author={Mohammad Reza Safarinejad},
  journal={Journal of Clinical Psychopharmacology},
  year={2008},
  volume={28},
  pages={39-44}
}
  • M. Safarinejad
  • Published 1 February 2008
  • Medicine
  • Journal of Clinical Psychopharmacology
Purpose: To evaluate the efficacy and safety of pindolol 7.5 mg/d in delaying of ejaculation in paroxetine-refractory patients. Materials and Methods: Eighty-six married men (mean age, 33 years) with premature ejaculation unresponsive to paroxetine 20 mg/d given for 2 months or longer were randomized to receive 7.5 mg pindolol (n = 44) (group 1) (PXT + POL) or placebo (n = 42) (group 2) (PXT + PBO) for 6 weeks, while continuing paroxetine. After 6 weeks, all patients received paroxetine and… 

The Efficacy and Safety of On-demand Tramadol and Paroxetine Use in Treatment of Life Long Premature Ejaculation: A Randomized Double-blind Placebo-controlled Clinical Trial

Tramadol may be considered as an appropriate alternative therapeutic option for lifelong PE after an increase in mean IELT and PEP scores in all 3 groups, and the rate of improvement in tramadol group was significantly more than the others.

Current Diagnosis and Management of Premature Ejaculation

Current evaluation and management of PE is discussed, with a review of all randomized, controlled trials performed, and the role of surgery in PE remains undefined, with additional data required.

Dapoxetine for Premature Ejaculation

The lack of ejaculatory control is consistent among all clinical definitions of PE and is a highly sensitive predictor of the condition.

Complementary, Surgical, and Experimental Modalities for Management of Premature Ejaculation

The majority of clinical research to date has focused on the condition now most clearly understood as lifelong PE, and there has been a recent movement towards subclassification of early ejaculation into four separate conditions.

‘Up and coming’ treatments for premature ejaculation: progress towards an approved therapy

A number of emerging therapies in various stages of development that show potential for use in the treatment of PE are reviewed, which may prove to offer the most favourable risk: benefit profile as well as the flexibility to adapt to differing frequencies of sexual activity.

Premature ejaculation: focus on therapeutic targets

There are many targets for future therapeutic approaches to PE that may address the shortcomings of existing therapy, but selecting the best targets depends heavily on their playing a prominent role in PE.

New Concepts in the Diagnosis and Treatment of Premature Ejaculation

Emerging medications and the ability to tailor treatments based on genetic information likely will change the paradigm of this disorder and how it will be treated by clinicians.

The integrity of seven randomized trials evaluating treatments for premature ejaculation

The investigation of the work of Dr Safarinejad found that many of these studies have shown the interventions to have a significant effect compared to placebo, and the natural course would be for the author to build on his earlier results with further studies.

β1- and β1/β2-adrenergic receptor antagonists block 6-nitrodopamine-induced contractions of the rat isolated epididymal vas deferens

It is demonstrated that β1- andβ1-/β2-adrenoceptor receptor antagonists act as 6-ND receptor antagonists in RIEVD, further confirming the main role of 6- ND in the RieVD contractility.

Management of male factor infertility: position statement from the Italian Society of Andrology and Sexual Medicine (SIAMS)

These Guidelines are couple-oriented and place high value in assessing, preventing, and treating risk factors for infertility and highlighted that male infertility and in particular testicular function might be a mirror of general health of a man.

References

SHOWING 1-10 OF 24 REFERENCES

Safety and efficacy of tramadol in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study.

Tramadol seems to provide significantly better results in terms of intravaginal ejaculatory latency time and intercourse satisfaction versus placebo, and further studies are required to draw final conclusions on the efficacy of this drug in premature ejaculation.

Tramadol HCL has promise in on-demand use to treat premature ejaculation.

Tramadol, a drug with a proven safety record as an anti-inflammatory agent, shows promise as a drug for treating rapid ejaculation.

Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression.

The results of these studies indicate that pindolol is safe when used in combination with an SSRI or moclobemide and should be tested under double-blind conditions to establish its efficacy.

Relevance of methodological design for the interpretation of efficacy of drug treatment of premature ejaculation: a systematic review and meta-analysis

At daily treatment, the overall efficacy of paroxetine, clomipramine, sertraline and fluoxetines is comparable, but paroxettine exerts the strongest ejaculation delay.

Augmentation of Fluoxetine's Antidepressant Action by Pindolol: Analysis of Clinical, Pharmacokinetic, and Methodologic Factors

A reanalysis of the data using a survival analysis revealed that significant differences in the time to sustained response between both groups would have also been detected in a 2-week trial, without a placebo lead-in phase, and with less frequent visits, emphasizing the need of using stringent outcome criteria in antidepressant drug trials.

A review of controlled trials in the pharmacological treatment of premature ejaculation.

There is a need for quality comparative trial of behavioural therapy, topical anaesthetic agents and antidepressants, including appropriate measures of relapse, follow-up and acceptability of continuing long-term treatment.

Selective Serotonin-Reuptake Inhibitors in the Treatment of Premature Ejaculation

Convenience and minimal adverse effect profile make SSRIs an alternative to previously used behavior modalities and older pharmacologic agents and have the potential to improve the quality of life for men with premature ejaculation and their partners.

Serotonin and premature ejaculation: from physiology to patient management.

Buspirone treatment of sexual dysfunction associated with selective serotonin re‐uptake inhibitors

The results suggest adjunctive buspirone may be useful in the management of sexual dysfunction associated with SSRIs; possible mechanisms of action are discussed.